Randall F. Holcombe, MD, MBA is director of the University of Hawai‘i Cancer Center, assuming this post in October 2016 and successfully leading the institution through NCI re-designation and CCSG renewal in 2017 and 2018.
He has held leadership roles in NCI and non-NCI designated cancer centers since 1989, serving as associate director of clinical and translational research at the Chao Family Comprehensive Cancer Center at the University of California, Irvine from 1997 through 2010, and as deputy director of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai from 2010 through 2016.
At Mount Sinai, Dr. Holcombe also served as chief medical officer-cancer for the Mount Sinai Health System and assisted with successful application for initial NCI designation for the Tisch Cancer Institute. Dr. Holcombe was a Duke undergraduate and received an MD from NJ Medical School and an MBA from the Zicklin School of Business at Baruch College. His post-doctoral clinical and research training was completed at Brigham & Women’s Hospital and Harvard Medical School in Boston.
Dr. Holcombe has over 25 years of experience in translational research and the conduct of oncology clinical trials. His research activities have focused on clinical investigations for patients with colorectal cancer, laboratory studies involving signaling pathways in the colon tumor microenvironment, the role of natural products in modulating cancer biology, and health care delivery science as a means to define new approaches for the delivery of quality cancer care.
For AACI, Dr. Holcombe served as a member of the AACI Clinical Research Initiative Steering Committee from 2012 to 2015 and as a member of the Steering Committee for the AACI Physician Clinical Leadership Initiative (PCLI) since 2015. He has served as Chair of the PCLI since 2016. Other professional responsibilities have included program chair for the 2018 AACI/CCAF Annual Meeting and a member of the editorial board for the Journal of Oncology Practice